Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain

• US 6,846,826 B2
• Filed: 03/26/2002
• Issued: 01/25/2005
• Est. Priority Date: 03/30/2001
• Status: Expired due to Fees

• Current Assignee: Ing-Jun Chen, Tong-Ho Lin
• Original Assignee: Ing-Jun Chen, Tong-Ho Lin
• Inventors: Chen, Ing-Jun
• Primary Examiner(s): Bernhardt, Emily
• Application Number:
  US10/105,265
• Publication Number:
  US 20030055066A1
• Time in Patent Office: 1,036 Days
• Field of Search: 544/365, 514/253.13, 514/356, 546/321, 546/322
• US Class Current: 514/253.13
• CPC Class Codes: C07D 213/80 in position 3

Abstract

Certain 1,4-dihydropyridine compounds, useful as adrenergic blocking agents and as calcium channel blocking agents, the compounds having the formula
wherein R¹ is hydrogen, halogen, C_1-6-alkyl, or C_1-6-alkoxy, R³ is hydrogen, halogen, C_1-6-alkyl, C_1-6-alkoxy, or CF₃(CH₂)_nO— wherein n is 1, 2, or 3, and R⁵ is —NHCH₂CH₂O— or —N(CH₂CH₂)₂N—.

Claims

1. A compound of the formula

wherein R¹ is halogen or C_1-6-alkoxy, R³ is hydrogen, halogen, C_1-6-alkyl, C_1-6-alkoxy, trifluoromethyl, or CF₃(CH₂)_nO—

wherein n is 1, 2, of 3, and R⁵ is

2. The compound of claim 1, wherein halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine.

3. The compound of claim 1, wherein R¹ is methoxy and R³ is chloro, namely, Labedipinedilol C.

4. A method of continuously maintaining hypotensive activity, which method comprises the step of treating a patient with a compound of claim 1, in a formulation containing diluents and/or excipients.

5. A compound of the formula

wherein R¹ is C_1-6-alkoxy, R³ is hydrogen, halogen, C_1-6alkyl, trifluoromethyl, or CF₃(CH₂)_nO—

wherein n is 1, 2, or 3, and R⁵ is —

NHCH₂CH₂O—

.

6. The compound of claim 5, wherein halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine.

7. The compound of claim 5, wherein R¹ is methoxy and R³ is methyl, namely, Labedipinedilol D.

8. The compound of claim 5, wherein R¹ is methoxy and R³ is chloro, namely, Labedipinedilol E.

9. The compound of claim 5, wherein R¹ is methoxy and R³ is trifluoromethyl, namely, Labedipinedilol F.

10. The compound of claim 5, wherein R¹ is methoxy and R³ is trifluoroethoxy, namely, Labedipinedilol G.

11. A method of continuously maintaining hypotensive activity, which method comprises the step of treating a patient with a compound of claim 5, in a formulation containing diluents and/or excipients.